Preparing for AI in Regulatory Submissions

Regulatory agencies are actively developing frameworks for the use of artificial intelligence across the drug-development lifecycle. For sponsors, the message is to engage early and document thoroughly. Where AI contributes to a submission — whether in trial design, data analysis, or safety monitoring — agencies will expect transparency about the model's purpose, validation, and the human oversight applied. Credibility assessment of AI models, proportional to their risk and influence on decisions, is emerging as a central theme. Taragal Research helps sponsors build this documentation discipline from the outset: defining each model's role, recording validation evidence, and demonstrating the human accountability behind every AI-supported decision. Trials designed with regulatory engagement in mind move through review with fewer surprises.